Business
ACT: EBITDA and net income surged in H1 2024, prompting a raised full-year outlook above €100M
ACT: EBITDA and net income surged in H1 2024, prompting a raised full-year outlook above €100M
About this update from Alzchem Group Ag
Alzchem delivered strong H1 2024 results, with sales up 3.3% and EBITDA up 41% year-over-year, driven by Specialty Chemicals. Net income nearly doubled, free cash flow surged, and the EBITDA outlook for 2024 was raised above €100M. Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.